Eli Lilly’s Q3 Earnings: Mounjaro Is Taking the World by Storm—See How It’s Conquering New Markets!

Eli Lilly and Company delivered a robust financial and operational performance in the third quarter of 2025. The company reported a 54% increase in revenue year-over-year, driven by strong sales of key drugs like Mounjaro and Zepbound. These products showed significant market penetration, particularly in the U.S., where Lilly has captured a dominant share of the incretin analogs market. Internationally, Mounjaro’s performance has also been exceptional, with significant uptake even in the absence of widespread reimbursement for obesity treatment, as many consumers pay out-of-pocket. Eli Lilly’s Q3 results also reflect strong operational practices with a gross margin of 83.6%, incrementally higher than the previous year, offset against moderate pricing pressures. Research and development (R&D) expenses rose by 27%, reflecting continued investments in an expanding pipeline. Marketing and administrative expenses also saw a 31% upsurge, aligned with product launch initiatives across geographies.